This was the stock's third consecutive day of gains.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The drug candidate is administered through oral route. It acts by targeting APO-L1 function. Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes ...

If you’re on the fence about investing in Vertex Pharmaceuticals Incorporated or AbbVie Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making ...

Vertex Pharmaceuticals (VRTX) closed at $469.29 in the latest trading session, marking a -0.99% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.3%.

Vertex had developed the candidate as a treatment for rheumatoid arthritis, taking it as far as a midphase trial in the setting. When EIP merged with Diffusion Pharmaceuticals last year to create ...